Daclizumab
Products Daclizumab was approved in the United States and EU in 2016 and in many countries in 2017 as a solution for injection for MS treatment (Zinbryta). In 2018, the drug was withdrawn from the market due to serious adverse effects. These adverse effects included liver damage and reports of encephalopathies (encephalitis, meningoencephalitis). Daclizumab had … Daclizumab
